Dr. George Carrum in Houston, TX

Dr. George Carrum, MD

Claim this profile

Houston Methodist Hospital

Studies Acute Lymphoblastic Leukemia
Studies Leukemia
7 reported clinical trials
25 drugs studied

Area of expertise

1Acute Lymphoblastic Leukemia
George Carrum, MD has run 3 trials for Acute Lymphoblastic Leukemia. Some of their research focus areas include:
HLA-A negative
HLA-A positive
HLA positive
2Leukemia
George Carrum, MD has run 3 trials for Leukemia. Some of their research focus areas include:
HLA-A negative
HLA-A positive
HLA positive

Affiliated Hospitals

Image of trial facility.
Houston Methodist Hospital
Image of trial facility.
Houston Methodist Cancer Center Methodist Cancer Center (2)

Clinical Trials George Carrum, MD is currently running

Image of trial facility.

HLA-matched VSTs

for Viral Infections Post Stem Cell Transplant

The purpose of this study is to use VSTs (virus-specific T cells) from a donor that is a partial HLA (human leukocyte antigen) match with the patient to treat viral infections after an allogeneic hematopoietic stem cell transplant (HSCT). These cells may also have value in CAR-T recipients who have received a product that depletes virus specific T cells. The patient must have had a myeloablative or non-myeloablative allogeneic HSCT using either bone marrow, single/double umbilical cord blood, or peripheral blood stem cells (PBSC) or CAR T cell product targeting an antigen expressed on virus specific T cells. After a transplant, while the immune system grows back, the patient is at risk for infection. Some viruses can stay in the body for life and are normally controlled by a healthy immune system, but if the immune system is weakened, like after a transplant, they can cause life threatening infections. He/she must have had an infection with one or more of the following viruses -Epstein Barr virus (EBV), cytomegalovirus (CMV), adenovirus (AdV), Human polyomavirus type I (BKV), and human polyomavirus type II (JCV)- that has persisted or recurred despite standard therapy. In this study, the investigators want to use white blood cells that have been trained to treat viral infections. In an earlier study the investigators showed that treatment with such specially trained T cells has been successful when the cells are made from the transplant donor. However as it takes 1-2 months to make the cells, that approach is not practical for patients who already have an infection. In a subsequent study, the investigators were able to create multivirus-specific T cells (VSTs) from the blood of healthy donors and created a bank of these cells. The investigators then successfully used these banked cells to treat virus infections after a stem cell transplant. In this study the investigators have further modified their production method to decrease the potential side effects and the investigators want to find out if they can use these banked VSTs to fight infections caused by the viruses mentioned above.
Recruiting1 award Phase 19 criteria

More about George Carrum, MD

Clinical Trial Related1 year of experience running clinical trials · Led 7 trials as a Principal Investigator · 1 Active Clinical Trial
Treatments George Carrum, MD has experience with
  • CTL019
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Best Practice
  • Clinical Management
  • Quality-of-Life Assessment
  • Questionnaire Administration

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does George Carrum, MD specialize in?
Is George Carrum, MD currently recruiting for clinical trials?
Are there any treatments that George Carrum, MD has studied deeply?
What is the best way to schedule an appointment with George Carrum, MD?
What is the office address of George Carrum, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security